AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16925684
Drug: Allergoid immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergoid immunotherapy
Trial: 11322745
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose at treatment endpoint = 0.05 mg/kg; mean total dose = 1.2 mg/day)
Trial: 9165504
Drug: High-dose toremifene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose toremifene (200 or 240 mg/d)
Trial: 9165504
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 or 40 mg/d)
Trial: 8427853
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss treatment groups
Trial: 29787858
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation counseling plus nicotine replacement therapy (C + NRT)
Trial: 22895351
Drug: 4 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg/d propranolol for 12 months postburn
Trial: 17910332
Drug: Allergen immunotherapy
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy with Culex quinquefasciatus extract
Trial: 11574763
Drug: Mito-FLAG protocol
RxNorm normalized name: Mito-4509
DrugBank: Mito-4509 (DB05846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mito-FLAG protocol (mitoxantrone 7 mg/m² days 1/3/5, fludarabine 15 mg/m² every 12 h days 1-5, cytarabine as bolus infusion 1000 mg/m² over 1 h every 12 h days 1-5)
Trial: 11574763
Drug: Mito-FLAG protocol
RxNorm normalized name: Mito-4509
DrugBank: Mito-4509 (DB05846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mito-FLAG protocol (cytarabine as continuous infusion 100-150 mg/m² over 24 h days 1-5)
Trial: 9692704
Drug: 1-hour topical
RxNorm normalized name: 3α-(diphenylmethoxy)-1αH,5αH-tropane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour topical method (bismuth, metronidazole, amoxycillin, pronase) after a 6-week course of ranitidine and omeprazole
Trial: 9692704
Drug: Amoxycillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (2 g/day) plus omeprazole (20 mg b.d.) for 2 weeks followed by a 4-week course of ranitidine
Trial: 7933682
Drug: ATP infusion
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP infusion at 0.16 mg/kg/min (group A)
Trial: 7933682
Drug: ATP infusion
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP infusion at 0.18 mg/kg/min (group B)
Trial: 7933682
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects from ATP infusion
Trial: 24679061
Drug: Clonidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.2 mg per day)
Trial: 22642525
Drug: Transdiagnostic cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic cognitive‐behavioral treatment (Unified Protocol for the Treatment of Emotional Disorders in Youth)
Trial: 19295325
Drug: ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe (10 mg)
Trial: 18072016
Drug: simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin (40 mg)
Trial: 16579717
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) for insomnia
Trial: 15598784
Drug: Calcitriol 0.5
RxNorm normalized name: CALCITRIOL 0.5MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.5 mug/kg weekly for 4 weeks
Trial: 9270645
Drug: Minimal-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minimal-dose aprotinin (1.0 x 10(6) KIU)
Trial: 9270645
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (2.7 +/- 0.5 x 10(6) KIU)
Trial: 9270645
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no aprotinin treatment)
Trial: 3130221
Drug: NORPLANT-2 implants
RxNorm normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NORPLANT-2 implants
Trial: 3130221
Drug: Both NORPLANT
RxNorm normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both NORPLANT and NORPLANT-2 implants
Trial: 16644323
Drug: BNP levels
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP levels < 100 pg/mL
Trial: 16644323
Drug: BNP levels
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP levels >= 100 pg/mL
Trial: 12475575
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (0.4‐0.8 mg/h)
Trial: 12475575
Drug: Intravenous fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fenoterol (60 ‐ 120 microg/h)
Trial: 10849527
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (CT) - Cycle 1: cytarabine 200 mg/m2/day (days 1-7) and idarubicin 12 mg/m2/day (days 1-2)
Trial: 10849527
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (CT) - Cycle 2: cytarabine 2000 mg/m2/day (days 1-6) and amsacrine 120 mg/m2/day (days 1-3)
Trial: 8473644
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin for > or = 10 days and no heparin (n = 12)
Trial: 8473644
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin for > or = 10 days but heparin, 10,000 IU, at the time of catheterization (n = 5)
Trial: 8473644
Drug: Aspirin, 300
RxNorm normalized name: Aspirin, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 300 mg/day, for at least 5 days (n = 11)
Trial: 8473644
Drug: Aspirin, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 75 mg/day for > or = 5 days before angioplasty (n = 11)
Trial: 8473644
Drug: Aspirin, 300
RxNorm normalized name: Aspirin, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 300 mg/day for > or = 3 days before angioplasty (n = 9)
Trial: 8473644
Drug: Aspirin, 300
RxNorm normalized name: Aspirin, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 300 mg/day for > or = 3 days before angioplasty followed by 1,000 mg during angioplasty (n = 9)
Trial: 2951806
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of fenoterol 200 micrograms and ipratropium bromide 80 micrograms
Trial: 31663831
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous thrombolysis plus mechanical thrombectomy (MT)
Trial: 31847977
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: papain 2% or 4% topical therapy, Unna boot compression therapy in phase 2
Trial: 31847977
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 2% hydrogel topical therapy, cellulose membrane followed by Unna boot compression therapy in phase 2
Trial: 31847977
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received single-layer elastic compression therapy (SurePress; ConvaTec) and educational activities, exercises, leg elevation, oral nutrition supplementation, and ulcer cleaning
Trial: 25515123
Drug: Bilateral cochlear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral cochlear implants (CI)
Trial: 11502917
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/day for 28 days, then 10 mg/day thereafter)
Trial: 9745423
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (starting dose, 10 +/- 0.3 micrograms/kg per day; mean treatment dose, 4 +/- 2 micrograms/kg per day)
Trial: 28619989
Drug: Alteplase (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (both doses)
Trial: 28073779
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion (2 pmol·kg‐1·min‐1)
Trial: 21079955
Drug: Topical cyanoacrylate
RxNorm normalized name: ethyl cyanoacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyanoacrylate applied every 3 to 5 days for 3 months
Trial: 2313465
Drug: ELISA test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELISA test with monoclonal antibodies against E. histolytica antigen
Trial: 29339527
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone every 2 weeks for 22 weeks
Trial: 26901417
Drug: Geriatric liaison
RxNorm normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geriatric liaison intervention (preoperative consultation, individual treatment plan, daily visits by a geriatric nurse)
Trial: 20622670
Drug: Riboflavin 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin 0.1% eyedrops for 1 month of topical use
Trial: 15936175
Drug: Lamotrigine (LTG),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG), mean daily dose of 250 mg
Trial: 15936175
Drug: Sodium Valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Valproate (VPA), mean daily dose of 2070 mg
Trial: 20180356
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg once daily
Trial: 9501262
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose fentanyl anesthesia (50 microg/kg with diazepam 0.1 mg/kg for induction, maintained with fentanyl 2 microg/kg/hr and diazepam 0.05 mg/kg/hr)
Trial: 9501262
Drug: Thiopentone anesthesia
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone anesthesia (7 mg/kg for induction, maintained with enflurane 0.7‐1.5% and thiopentone 3 mg/kg/hr during CPB)
Trial: 8580271
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily, Amoxycillin 500 mg t.d.s., Metronidazole 400 mg t.d.s. for 14 days
Trial: 8580271
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily, Amoxycillin 500 mg t.d.s. and placebo for 14 days
Trial: 29266180
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 0.4% dexamethasone added to 18 ml 0.5% bupivacaine‐epinephrine
Trial: 29266180
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml 0.9% normal saline added to 18 ml 0.5% bupivacaine‐epinephrine
Trial: 23043368
Drug: CNTO 5825
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 5825 (0.1, 0.3, 1.0, 3.0, or 10 mg kg(‐1) i.v. or 3.0 mg kg(‐1) s.c.)
Trial: 23043368
Drug: CNTO 5825
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 5825 (10 mg kg(‐1) i.v.) in healthy atopic subjects
Trial: 21127156
Drug: Probiotic E.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic E. coli strain Nissle 1917 (Mutaflor), administered at a daily dose of 5×10(9)‐5×10(10) bacteria, twice daily.
Trial: 18781073
Drug: Yacon syrup
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yacon syrup (20 g daily, equal to 6.4 g FOS)
Trial: 16438769
Drug: Infero-nasal sub-Tenon's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infero-nasal sub-Tenon's injection of lidocaine 2% with hyaluronidase 15 IU mL‐1
Trial: 16438769
Drug: Infero-temporal sub-Tenon's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infero-temporal sub-Tenon's injection of lidocaine 2% with hyaluronidase 15 IU mL‐1
Trial: 12492739
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (proton pump inhibitor plus amoxicillin and clarithromycin for 1 week)
Trial: 12492739
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor alone for 8 weeks
Trial: 12492739
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (for ulcers of < 1.0 cm)
Trial: 12492739
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor alone (for ulcers of < 1.0 cm)
Trial: 12492739
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (for ulcers of 1.0 to < 1.5 cm)
Trial: 12492739
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor alone (for ulcers of 1.0 to < 1.5 cm)
Trial: 12492739
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (for ulcers of > or = 1.5 cm)
Trial: 12492739
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor alone (for ulcers of > or = 1.5 cm)
Trial: 10865302
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (75, 150, or 225 mg/d)
Trial: 7902034
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg and 0.9 mg/kg
Trial: 3030619
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (mean dose: 29 g)
Trial: 3030619
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran (mean dose: 33 g)
Trial: 29574039
Drug: E39 peptide
RxNorm normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E39 peptide vaccine (500 μg or 1000 μg)
Trial: 29574039
Drug: E39 followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E39 followed by E39' (500 μg or 1000 μg)
Trial: 29574039
Drug: E39' followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E39' followed by E39 (500 μg or 1000 μg)
Trial: 11010060
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine 0.5% ophthalmic solution, instilled four times daily for 6 weeks
Trial: 11010060
Drug: Levocabastine 0.05%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine 0.05%, instilled four times daily for 6 weeks
Trial: 11010060
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine vehicle, instilled four times daily for 6 weeks
Trial: 8617884
Drug: Adenovirus vector
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus vector encoding cystic fibrosis transmembrane conductance regulator, administered to the nasal epithelium with five escalating doses of up to 10(10) infectious units.
Trial: 8617884
Drug: Adenovirus vector
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus vector encoding cystic fibrosis transmembrane conductance regulator, administered to the nasal epithelium.
Trial: 1306646
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immune globulin (HDivIG) therapy at 500 mg/kg for a 2-hour period
Trial: 8499737
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment including phototherapy
Trial: 1306646
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immune globulin (HDivIG) therapy
Trial: 6378236
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (200 mg four times daily for six weeks)
Trial: 25440807
Drug: Sevoflurane inhalation
RxNorm normalized name: Sevoflurane Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane inhalation
Trial: 29361285
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy (Simvastatin and Ezetimibe)
Trial: 21043369
Drug: Intravaginal gel
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal gel (Prepidil)
Trial: 16563861
Drug: Self-massage and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-massage and skin care using a cream containing aromatherapy oils
Trial: 16563861
Drug: Self-massage and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-massage and skin care using a cream without aromatherapy oils
Trial: 11688002
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg intravenously)
Trial: 26718578
Drug: 10,400 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,400 IU cholecalciferol daily for 6 months
Trial: 26718578
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU cholecalciferol daily for 6 months
Trial: 17919763
Drug: Glimepiride 3mg
RxNorm normalized name: GLIMEPIRIDE 3MG TAB
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride 3mg (morning) and insulin glargine (bedtime) with dose titration
Trial: 10392329
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg and 10 mg, diltiazem 200 mg and 300 mg, mibefradil 50 mg and 100 mg
Trial: 10392329
Drug: Mibefradil (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil (low dose)
Trial: 10392329
Drug: Mibefradil (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil (high dose)
Trial: 8888913
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron therapy for adolescents with s-ferritin < 12 micrograms l-1
Trial: 1986667
Drug: Budesonide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (400 micrograms twice daily)
Trial: 3885387
Drug: Dextromethorphan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (20 mg)
Trial: 3885387
Drug: Codeine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (20 mg)
Trial: 20632489
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (Group A)
Trial: 20075385
Drug: Disease management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease management program (single 1- to 1.5-hour education session, action plan for self-treatment of exacerbations, monthly follow-up calls)
Trial: 18578170
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide solution (Opalescence)
Trial: 18578170
Drug: 22% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22% carbamide peroxide solution (Nite White Excel 3)
Trial: 16055224
Drug: Matrix-in-cylinder system
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix-in-cylinder system (80 mg propranolol hydrochloride)
Trial: 16055224
Drug: Matrix-in-cylinder system
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix-in-cylinder system (80 mg propranolol hydrochloride) under fed conditions
Trial: 16055224
Drug: Matrix-in-cylinder system
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix-in-cylinder system (80 mg propranolol hydrochloride) under fasted conditions
Trial: 16055224
Drug: Inderal (commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inderal (commercial pellet formulation)
Trial: 10356104
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone or in combination with low doses of warfarin
Trial: 10356104
Drug: Estrogen hormone
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen hormone replacement therapy among SPAF III participants
Trial: 1954814
Drug: Usual insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual insulin (isoglycemic study)